All In Biotech

Drug Trial Radar · NCT05330975

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered With a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults ≥ 50 Years of Age

Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,317 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,317

Actual

Start

Apr 1, 2022

Primary completion

Nov 8, 2024

Study completion Nov 8, 2024

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Apr 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of coadministered influenza vaccine on the immune response to RSV-A; and to evaluate the impact of coadministered RSV vaccine on the immune response to influenza. The main purposes of Part B of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with mRNA-1273.214; to evaluate the effect of coadministered mRNA-1273.214 on the immune response to RSV-A; and to evaluate the effect of coadministered RSV vaccine on the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main purposes of Part C (single arm, open-label) of this study are to evaluate the safety and tolerability of a booster dose (BD) of mRNA-1345 administered at 1 Year following a primary dose; to evaluate the immune response to RSV-A of a BD of mRNA 1345 administered at 1 Year following a primary dose; and to evaluate the immune response to RSV-B of a BD of mRNA-1345 administered at 1 Year following a primary dose.

Conditions

  • Respiratory Syncytial Virus

Interventions

  • PlaceboBiological

    0.9% sodium chloride (normal saline) injection

  • mRNA-1345Biological

    Sterile liquid for injection

  • Afluria® QuadrivalentBiological

    single-dose, pre-filled syringe for injection

  • mRNA-1273.214Biological

    Sterile liquid for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 InjectionTime frame: Within 7 days after Day 1 injection
  2. Part A: Number of Participants With Unsolicited Adverse Events (AEs) After Day 1 InjectionTime frame: Day 1 through Day 28 (28 days after Day 1 injection)
  3. Part A: Number of Participants With Medically Attended AEs (MAAEs), SAEs, Adverse Events of Special Interest (AESIs), and AEs Leading to WithdrawalTime frame: Day 1 through Day 181 (end of Study Part A)
  4. Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) Neutralizing Antibodies (NAbs) at Day 29Time frame: Day 29
  5. Part A: Percentage of Participants With Seroresponse in RSV-A NAbs at Day 29Time frame: Day 29
  6. Part A: GMT of Serum Anti-hemagglutination (HA) Ab Level, as Measured by Hemagglutination Inhibition (HAI) Assay for Influenza at Day 29Time frame: Day 29
  7. Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 1 InjectionTime frame: Within 7 days after Day 1 injection
  8. Part B: Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 29 InjectionTime frame: Within 7 days after Day 29 injection
  9. Part B: Number of Participants With Unsolicited AEs After Day 1 InjectionTime frame: Day 1 through Day 28 (28 days after Day 1 injection)
  10. Part B: Number of Participants With Unsolicited AEs After Day 29 InjectionTime frame: Day 29 through Day 57 (28 days after Day 29 injection)
  11. Part B: Number of Participants With MAAEs, SAEs, AESIs, and AEs Leading to WithdrawalTime frame: Day 1 through Day 211
  12. Part B: GMT of Serum RSV-A at Day 29Time frame: Day 29
  13. Part B: Percentage of Participants With Seroresponse for RSV-A Neutralizing Abs From Baseline to Day 29Time frame: Baseline to Day 29
  14. Part B: Geometric Mean Concentration (GMC) of Serum Ab Level, as Measured by Neutralization Assay for SARS-Cov-2 at Day 29Time frame: Day 29
  15. Part B: Percentage of Participants With Seroresponse for SARS-Cov-2 NAbs From Baseline to Day 29Time frame: Baseline to Day 29
  16. Part C: Number of Participants With Solicited Local and Systemic Within 7 Days After Revaccination Day 1Time frame: Within 7 days after Day 1 revaccination
  17. Part C: Number of Participants With Unsolicited AEs Within 28 Days After Revaccination Day 1Time frame: Revaccination Day 1 through Day 28 (28 days after revaccination Day 1)
  18. Part C: Number of Participants With MAAEsTime frame: Revaccination Day 1 through Day 181
  19. Part C: Number of Participants With SAEs, AESIs, and AEs Leading to WithdrawalTime frame: Revaccination Day 1 through Day 361
  20. Part C: GMT of Serum RSV-A and RSV-B NAbs mRNA-1345 Revaccination Day 29 Compared to Primary Vaccination Day 29Time frame: Primary Vaccination Day 29 to Revaccination Day 29

Locations

62 sites in 1 country. Site status is shown where the registry gives one.

  • Central Research Associates Inc

    Birmingham, Alabama

  • Del Sol Research Management - Clinedge - PPDS

    Tucson, Arizona

  • Paragon Rx Clinical, Inc

    Garden Grove, California

  • Ark Clinical Research

    Long Beach, California

  • Long Beach Clinical Trials, LLC (Site 1)

    Long Beach, California

  • Long Beach Clinical Trials, LLC (Site 2)

    Long Beach, California

  • Central Valley Research, LLC

    Modesto, California

  • Velocity Clinical Research - Panorama City

    Panorama City, California

  • Empire Clinical Research

    Pomona, California

  • Acclaim Clinical Research

    San Diego, California

  • Medical Center For Clinical Research - M3 WR - ERN - PPDS

    San Diego, California

  • Ark Clinical Research

    Tustin, California

  • Chase Medical Research LLC

    Waterbury, Connecticut

  • Teradan Clinical Trials

    Brandon, Florida

  • Revival Research Corporation - Clinedge - PPDS

    Doral, Florida

  • Dolphin Medical Research

    Doral, Florida

  • Indago Research and Health Center

    Hialeah, Florida

  • Westside Center for Clinical Research - ERN - PPDS

    Jacksonville, Florida

  • Suncoast Research Group LLC - ERN-PPDS

    Miami, Florida

  • Suncoast Research Associates LLC - ERN - PPDS

    Miami, Florida

  • Floridian Clinical Research - ClinEdge - PPDS

    Miami Lakes, Florida

  • Tekton Research - Georgia - Platinum - PPDS

    Chamblee, Georgia

  • Lifeline Primary Care / CCT Research

    Lilburn, Georgia

  • Georgia Clinic / CCT Research

    Norcross, Georgia

  • Meridian Clinical Research (Savannah Georgia) - Platinum - PPDS

    Savannah, Georgia

  • East-West Medical Research Institute

    Honolulu, Hawaii

  • Meridian Clinical Research (Sioux City - Iowa)

    Sioux City, Iowa

  • Meridian Clinical Research, LLC (Overland Park, Kansas) - Platinum - PPDS

    Overland Park, Kansas

  • Meridian Clinical Research (Baton Rouge-Louisiana) - Platinum - PPDS

    Baton Rouge, Louisiana

  • Clinical Trials of SWLA, LLC

    Lake Charles, Louisiana

  • Meridian Clinical Research (Rockville Maryland) - Platinum - PPDS

    Rockville, Maryland

  • Clinical Research Institute, Inc - CRN - PPDS

    Minneapolis, Minnesota

  • Meridian Clinical Research (Grand Island) - Platinum - PPDS

    Grand Island, Nebraska

  • Meridian Clinical Research, LLC (Lincoln Nebraska) - Platinum - PPDS

    Lincoln, Nebraska

  • Be Well Clinical Studies, LLC

    Lincoln, Nebraska

  • Meridian Clinical Research

    Norfolk, Nebraska

  • Meridian Clinical Research (Omaha-Nebraska) - Platinum - PPDS

    Omaha, Nebraska

  • Midwest Regional Health Services - CCT Research

    Omaha, Nebraska

  • Clinical Research Center of Nevada - ERN - PPDS

    Las Vegas, Nevada

  • Santa Rosa Medical Centers of Nevada - CCT Research

    Las Vegas, Nevada

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.